How‐Wen Ko

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

Chien‐Ying Liu, Chih‐Liang Wang, Shih‐Hong Li et al. · Oncotarget · 2017 · 31 citations · Full text

Medicine, Oncology, Pharmacology +15

Effects of hydroxyethyl starch resuscitation on extravascular lung water and pulmonary permeability in sepsis-related acute respiratory distress syndrome *

Chung-Chi Huang, Kuo‐Chin Kao, Kuang‐Hung Hsu et al. · Critical Care Medicine · 2009 · 30 citations

Medicine, Pharmacokinetics, Pulmonology +16

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer

Chih‐Hsi S. Kuo, Chin‐Chou Wang, Yu‐Chen Huang et al. · Thoracic Cancer · 2019 · 22 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Jia‐Shiuan Ju, Allen Chung‐Cheng Huang, Pi‐Hung Tung et al. · Scientific Reports · 2023 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma

Chun‐Wei Lu, Jong‐Hwei S. Pang, Yu‐Shien Ko et al. · Journal of the European Academy of Dermatology and Venereology · 2022 · 17 citations

Medicine, Dermatology, Oncology +17